Cabozantinib
- Generic Name
- Cabozantinib
- Brand Names
- Cabometyx, Cometriq
- Drug Type
- Small Molecule
- Chemical Formula
- C28H24FN3O5
- CAS Number
- 849217-68-1
- Unique Ingredient Identifier
- 1C39JW444G
- Background
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.
- Indication
⑴治疗进展的、不能切除的局部晚期或转移的髓性甲状腺癌。
⑵用于舒尼替尼（索坦）治疗失败的晚期肾癌。
- Associated Conditions
- Advanced Renal Cell Carcinoma, Hepatocellular Carcinoma, Metastatic Differentiated Thyroid Cancer, Locally advanced Differentiated Thyroid Cancer (DTC), Metastatic Clear Cell Renal Cell Carcinoma (ccRCC), Progressive, metastatic Medullary thyroid cancer
- Associated Therapies
- -
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 222
- Registration Number
- NCT00704288
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 92
- Registration Number
- NCT00596648
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Georgetown University/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸Park Nicollet Institute, St. Louis Park, Minnesota, United States
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 85
- Registration Number
- NCT00215605
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.